Esperion: Enough Cash On Hand To Bring Cholesterol-Buster To Market
ANN ARBOR — The pharma startup Esperion Therapeutics Inc. (Nasdaq: ESPR) told its investors this week that following a $200 million public stock sale in March, it “estimates that current …